Swollen lymph nodes in the neck in someone with infectious mononucleosis
|Classification and external resources|
|eMedicine||emerg/319 med/1499 ped/705|
|Patient UK||Infectious mononucleosis|
Infectious mononucleosis (IM; also known as mono, glandular fever, Pfeiffer's disease, Filatov's disease, and sometimes colloquially as the kissing disease from its transmission by saliva) is an infectious, widespread viral disease most commonly caused by the Epstein–Barr virus (EBV), one type of herpes virus, against which over 90% of adults are likely to have acquired immunity by the age of 40. Occasionally, the symptoms can reoccur at a later period. Most people are exposed to the virus as children, when the disease produces no noticeable or only flu-like symptoms. In developing countries, people are exposed to the virus in early childhood more often than in developed countries. As a result, the disease in its observable form is more common in developed countries. It is most common among adolescents and young adults.
Especially in adolescents and young adults, the disease is characterized by fever, sore throat and fatigue, along with several other possible signs and symptoms. It is primarily diagnosed by observation of symptoms, but suspicion can be confirmed by several diagnostic tests. It is generally a self-limiting disease, and little treatment is normally required.
- 1 Signs and symptoms
- 2 Cause
- 3 Pathophysiology
- 4 Diagnosis
- 5 Treatment
- 6 Prognosis
- 7 History
- 8 References
- 9 External links
Signs and symptoms
The signs and symptoms of infectious mononucleosis vary with age. The exact length of time between infection and symptoms is unclear. A review of the literature made an estimate of 33–49 days. In adolescents and young adults, symptoms are thought to appear around 4–6 weeks after initial infection. Onset is often gradual, though it can be abrupt. The main symptoms may be preceded by 1–2 weeks of fatigue, feeling unwell and body aches.
In infancy and pre-adolescence, the disease produces only flu-like symptoms, if any at all. When found, symptoms tend to be similar to those of common throat infections (mild pharyngitis, with or without tonsillitis).
Adolescents and young adults
- Fever – usually lasting 10–14 days; often mild, especially in the last 5–7 days.
- Sore throat (acute pharyngitis) – usually severe for 3–5 days, before resolving in the next 7–10 days.
- Swollen glands (lymphadenopathy) – mobile; usually located around the back of the neck (posterior cervical lymph nodes) and sometimes throughout the body.
Another major symptom is exhaustion (fatigue). Headaches are common, and abdominal pains with nausea or vomiting sometimes also occur. Symptoms most often disappear after about 2–3 weeks. However, fatigue and a general feeling of being unwell (malaise) may sometimes last for months. Fatigue lasts more than one month in an estimated 9–22% of cases. In cases where fatigue lingers, it generally passes spontaneously within 2 years. Mild fever, swollen neck glands and body aches may also persist beyond 4 weeks. Most people are able to resume their usual activities within 2–3 months.
The most prominent sign of the disease is often the pharyngitis, which is frequently accompanied by enlarged tonsils with pus—an exudate similar to that seen in cases of strep throat. In about 50% of cases, small reddish-purple spots called petechiae can be seen on the roof of the mouth. Palatal enanthem can also occur, but is relatively uncommon.
Spleen enlargement is common in the second and third weeks, although this may not be apparent on physical examination. Rarely the spleen may rupture. There may also be some enlargement of the liver. Jaundice occurs only occasionally.
A small minority of people spontaneously present a rash, usually on the arms or trunk, which can be macular (morbilliform) or papular. Almost all people given amoxicillin or ampicillin eventually develop a generalized, itchy maculopapular rash, which however does not imply that the person will have adverse reactions to penicillins again in the future. Occasional cases of erythema nodosum and erythema multiforme have been reported.
Infectious mononucleosis mainly affects younger adults. When older adults do catch the disease, they less often have characteristic signs and symptoms such as the sore throat and lymphadenopathy. Instead, they may primarily experience prolonged fever, fatigue, malaise and body pains. They are more likely to have liver enlargement and jaundice. People over 40 years of age are more likely to develop serious illness. (See Prognosis.)
About 90% of cases of infectious mononucleosis are caused by the Epstein–Barr virus, a member of the Herpesviridae family of DNA viruses. It is one of the most commonly found viruses throughout the world. Contrary to common belief, the Epstein–Barr virus is not highly contagious. It can only be contracted through direct contact with an infected person’s saliva, such as through kissing or sharing toothbrushes, cups, etc. About 95% of the population has been exposed to this virus by the age of 40, but only 15–20% of teenagers and about 40% of exposed adults actually become infected.
A minority of cases of infectious mononucleosis are caused by human cytomegalovirus (CMV), another type of herpes virus. This virus is found in body fluids including saliva, urine, blood, and tears. A person becomes infected with this virus by direct contact with infected body fluids. Cytomegalovirus is most commonly transmitted through kissing and sexual intercourse. It can also be transferred from an infected mother to her unborn child. This virus is often "silent" because the signs and symptoms cannot be felt by the person infected. However, it can cause life-threatening illness in infants, HIV patients, transplant recipients, and those with weak immune systems. For those with weak immune systems, cytomegalovirus can cause more serious illnesses such as pneumonia and inflammations of the retina, esophagus, liver, large intestine, and brain. Approximately 90% of the human population has been infected with cytomegalovirus by the time they reach adulthood, but most are unaware of the infection. Once a person becomes infected with cytomegalovirus, the virus stays in his/her body fluids throughout his or her lifetime.
Epstein–Barr virus infection is spread via saliva, and has an incubation period of four to seven weeks. The length of time that an individual remains contagious is unclear, but the chances of passing the illness to someone else may be the highest during the first six weeks following infection. Some studies indicate that a person can spread the infection for many months, possibly up to a year and a half.
The virus replicates first within epithelial cells in the pharynx (which causes pharyngitis, or sore throat), and later primarily within B cells (which are invaded via their CD21). The host immune response involves cytotoxic (CD8-positive) T cells against infected B lymphocytes, resulting in enlarged, atypical lymphocytes (Downey cells).
Cytomegalovirus, adenovirus and Toxoplasma gondii (toxoplasmosis) infections can cause symptoms similar to infections mononucleosis, but a heterophile antibody test will test negative and differentiate those infections from infectious mononucleosis.
Mononucleosis is sometimes accompanied by secondary cold agglutinin disease, an autoimmune disease in which abnormal circulating antibodies directed against red blood cells can lead to a form of autoimmune hemolytic anemia. The cold agglutinin detected is of anti-i specificity.
The most commonly used diagnostic criterion is the presence of 50% lymphocytes with at least 10% atypical lymphocytes (large, irregular nuclei), while the person also has fever, pharyngitis and adenopathy. Furthermore, it should be confirmed by a serological test. The atypical lymphocytes resembled monocytes when they were first discovered, thus the term "mononucleosis" was coined. Diagnostic tests are used to confirm infectious mononucleosis, but the disease should be suspected from symptoms prior to the results from hematology. These criteria are specific; however, they are not particularly sensitive and are more useful for research than for clinical use. Only half of the patients presenting with the symptoms held by mononucleosis and a positive heterophile antibody test (monospot test) meet the entire set of criteria. One key procedure is to differentiate between infectious mononucleosis and mononucleosis-like symptoms.
A few studies on infectious mononucleosis have been conducted in a primary care environment, the best of which studied 700 patients, of which 15 were found to have mononucleosis upon a heterophile antibody test. More useful in a diagnostic sense are the signs and symptoms themselves. The presence of splenomegaly, and posterior cervical, axillary and inguinal adenopathies are the most useful to suspect a diagnosis of infectious mononucleosis. On the other hand, the absence of cervical adenopathy and fatigue are the most useful to dismiss the idea of infectious mononucleosis as the correct diagnosis. The insensitivity of the physical examination in detecting splenomegaly means it should not be used as evidence against infectious mononucleosis.
In the past, the most common test for diagnosing infectious mononucleosis was the heterophile antibody test, which involves testing heterophile antibodies by agglutination of guinea pig, sheep and horse red blood cells. As with the aforementioned criteria, this test is specific but not particularly sensitive (with a false-negative rate of as high as 25% in the first week, 5–10% in the second, and 5% in the third). About 90% of patients have heterophile antibodies by week 3, disappearing in under a year. The antibodies involved in the test do not interact with the Epstein–Barr virus or any of its antigens. More recently, more sensitive tests have been developed, such as the immunoglobulin G (IgG) and immunoglobulin M (IgM) tests. IgG, when positive, reflects a past infection, whereas IgM reflects a current infection. When negative, these tests are more accurate in ruling out infectious mononucleosis. However, when positive, they feature similar sensitivities to the heterophile antibody test. Therefore, these tests are useful for diagnosing infectious mononucleosis in people with highly suggestive symptoms and a negative heterophile antibody test. Another test searches for the Epstein–Barr nuclear antigen, while it is not normally recognizable until several weeks into the disease, and is useful for distinguishing between a recent-onset of infectious mononucleosis and symptoms caused by a previous infection. Elevated hepatic transaminase levels is highly suggestive of infectious mononucleosis, occurring in up to 50% of patients.
A fibrin ring granuloma may be present.
About 10% of people who present a clinical picture of infectious mononucleosis do not have an acute Epstein–Barr-virus infection. A differential diagnosis of acute infectious mononucleosis needs to take into consideration acute cytomegalovirus infection and Toxoplasma gondii infections. Because their management is much the same, it is not always helpful, or possible, to distinguish between Epstein–Barr-virus mononucleosis and cytomegalovirus infection. However, in pregnant women, differentiation of mononucleosis from toxoplasmosis is important, since it is associated with significant consequences for the fetus.
Patients with infectious mononucleosis are sometimes misdiagnosed with a streptococcal pharyngitis (because of the classical clinical triad of fever, pharyngitis and adenopathy) and are given antibiotics such as ampicillin or amoxicillin as treatment.
Infectious mononucleosis is generally self-limiting, so only symptomatic and/or supportive treatments are used. The need for rest and return to usual activities after the acute phase of the infection may reasonably be based on the person's general energy levels. In particular, bed rest need not be prescribed, and a return to normal activities is desirable as soon as it is comfortable for them to be resumed (gradually, if necessary). Nevertheless, in an effort to decrease the risk of splenic rupture experts advise avoidance of contact sports and other heavy physical activity, especially when involving increased abdominal pressure or the Valsalva maneuver (as in rowing or weight training), for at least the first 3–4 weeks of illness or until splenomegaly has resolved, as determined by a treating physician.
Paracetamol (acetaminophen) or NSAIDs, such as ibuprofen, may be used to reduce fever and pain. Prednisone, a corticosteroid, is commonly used as an anti-inflammatory to reduce symptoms of pharyngeal pain, odynophagia, or enlarged tonsils, although its use remains controversial due to the rather limited benefit and the potential of side effects. Intravenous corticosteroids, usually hydrocortisone or dexamethasone, are not recommended for routine use but may be useful if there is a risk of airway obstruction, severe thrombocytopenia, or hemolytic anemia. There is little evidence to support the use of aciclovir, although it may reduce initial viral shedding. However, the antiviral drug valacyclovir has recently been shown to lower or eliminate the presence of the Epstein–Barr virus in subjects afflicted with acute mononucleosis, leading to a significant decrease in the severity of symptoms. Although antivirals are not recommended for patients presenting with simple infectious mononucleosis, they may be useful (in conjunction with steroids) in the management of patients with severe EBV manifestations, such as EBV meningitis, peripheral neuritis, hepatitis, or hematologic complications.
Although antibiotics exert no antiviral action they may be indicated to treat bacterial secondary infections of the throat, such as with streptococcus (strep throat). However, ampicillin and amoxicillin are contraindicated during acute Epstein–Barr virus infection since the vast majority of patients treated with them develop a diffuse non-allergic rash.
Splenomegaly is a common symptom of infectious mononucleosis and health care providers may consider using abdominal ultrasonography to get insight into the enlargement of a person's spleen. However, because spleen size varies greatly, ultrasonography is not a valid technique for assessing spleen enlargement and should not be used in typical circumstances or to make routine decisions about fitness for playing sports.
- CNS complications include meningitis, encephalitis, hemiplegia, Guillain-Barré syndrome, and transverse myelitis. Infection with the Epstein–Barr virus has also been proposed as a risk factor for the development of multiple sclerosis (MS), but this has not been confirmed.
- Hematologic: Hemolytic anemia (direct Coombs test is positive) and various cytopenias, and bleeding (caused by thrombocytopenia) can occur.
- Mild jaundice
- Hepatitis with the Epstein–Barr virus is rare.
- Upper airway obstruction from tonsillar hypertrophy is rare.
- Fulminant disease course of immunocompromised patients is rare.
- Splenic rupture is rare.
- Myocarditis and pericarditis are rare.
- Postural orthostatic tachycardia syndrome
- Chronic fatigue syndrome
- Cancers associated with the Epstein-Barr virus include: Burkitt's lymphoma, Hodgkin's lymphoma and lymphomas in general as well as nasopharyngeal and gastric carcinoma.
Once the acute symptoms of an initial infection disappear, they often do not return. But once infected, the patient carries the virus for the rest of his or her life. The virus typically lives dormantly in B lymphocytes. Independent infections of mononucleosis may be contracted multiple times, regardless of whether the patient is already carrying the virus dormantly. Periodically, the virus can reactivate, during which time the patient is again infectious, but usually without any symptoms of illness. Usually, a patient has few, if any, further symptoms or problems from the latent B lymphocyte infection. However, in susceptible hosts under the appropriate environmental stressors, the virus can reactivate and cause vague physical symptoms (or may be subclinical), and during this phase the virus can spread to others.
The characteristic symptomatology of infectious mononucleosis does not appear to have been reported until the late nineteenth century. In 1885, the renowned Russian pediatrician Nil Filatov reported an infectious process he called "idiopathic denitis" exhibiting symptoms that correspond to infectious mononucleosis, and in 1889 a German balneologist and pediatrician, Emil Pfeiffer, independently reported similar cases (some of lesser severity) that tended to cluster in families, for which he coined the term Drüsenfieber ("glandular fever").
The word mononucleosis has several senses. It can refer to any monocytosis (excessive numbers of circulating monocytes), but today it usually is used in its narrower sense of infectious mononucleosis, which is caused by EBV and of which monocytosis is a finding.
The term "infectious mononucleosis" was coined in 1920 by Thomas Peck Sprunt and Frank Alexander Evans in a classic clinical description of the disease published in the Bulletin of the Johns Hopkins Hospital, entitled "Mononuclear leukocytosis in reaction to acute infection (infectious mononucleosis)".
The Epstein–Barr virus was first identified in Burkitt's lymphoma cells by Michael Anthony Epstein and Yvonne Barr at the University of Bristol in 1964. The link with infectious mononucleosis was uncovered in 1967 by Werner and Gertrude Henle at the Children's Hospital of Philadelphia, after a laboratory technician handling the virus contracted the disease: comparison of serum samples collected from the technician before and after the onset revealed development of antibodies to the virus.
- Filatov's disease at Who Named It?
- "Epstein-Barr Virus and Infectious Mononucleosis". CDC A–Z Index. National Center for Infectious Diseases. 16 May 2006. Retrieved December 6, 2009.
- "Glandular fever". NICE Clinical Knowledge Summaries. cks.nice.org.uk. 2010. Retrieved 15 June 2013.
- Stöppler, Melissa Conrad (7 September 2011). Shiel, William C. Jr., ed. "Infectious Mononucleosis (Mono)". MedicineNet. medicinenet.com. Retrieved 18 June 2013.
- Richardson, M; Elliman, D; Maguire, H; Simpson, J; Nicoll, A (April 2001). "Evidence base of incubation periods, periods of infectiousness and exclusion policies for the control of communicable diseases in schools and preschools". The Pediatric Infectious Disease Journal 20 (4): 380–91. doi:10.1097/00006454-200104000-00004. PMID 11332662.
- Cohen, Jeffrey I. (2008). "Epstein-Barr Infections, Including Infectious Mononucleosis". In Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J. Harrison's principles of internal medicine (17th ed.). New York: McGraw-Hill Medical Publishing Division. pp. 380–91. ISBN 978-0-07-146633-2.
- Odumade, OA; Hogquist, KA; Balfour HH, Jr (January 2011). "Progress and problems in understanding and managing primary Epstein-Barr virus infections". Clinical Microbiology Reviews 24 (1): 193–209. doi:10.1128/CMR.00044-10. PMC 3021204. PMID 21233512. Retrieved 20 June 2013.
- Cohen, Jeffrey I. (2005). "Clinical Aspects of Epstein-Barr Infection". In Robertson, Erle S. Epstein-Barr Virus. Horizon Scientific Press. pp. 35–42. ISBN 978-1-904455-03-5. Retrieved 18 June 2013.
- Weiss, LM; O'Malley, D (2013). "Benign lymphadenopathies". Modern Pathology 26 (Supplement 1): S88–S96. doi:10.1038/modpathol.2012.176. PMID 23281438.
- Johannsen, EC; Kaye, KM (2009). "Epstein-Barr virus (infectious mononucleosis, Epstein-Barr virus-associated malignant disease, and other diseases)". In Mandell, GL; Bennett, JE; Dolin, R. Mandell, Douglas, and Bennett's principles and practice of infectious disease (7th ed.). Philadelphia: Churchill Livingstone. ISBN 978-0443068393.
- Luzuriaga, K; Sullivan, JL (May 27, 2010). "Infectious mononucleosis". The New England Journal of Medicine 362 (21): 1993–2000. doi:10.1056/NEJMcp1001116. PMID 20505178.
- Ebell MH (November 2004). "Epstein-Barr virus infectious mononucleosis". American Family Physician 70 (7): 1279–87. PMID 15508538.
- Evans, Alfred S. (1 January 1948). "Liver involvement in infectious mononucleosis". Journal of Clinical Investigation 27 (1): 106–110. doi:10.1172/JCI101913. PMC 439479.
- Mononucleosis and Epstein-Barr: What's the connection?. MayoClinic.com (2011-11-22). Retrieved on 2013-08-03.
- Schonbeck, John and Frey, Rebecca. The Gale Encyclopedia of Medicine. Vol. 2. 4th ed. Detroit: Gale, 2011. Online.
- Larsen, Laura. Sexually Transmitted Diseases Sourcebook. Health Reference Series Detroit: Omnigraphics, Inc., 2009. Online.
- Carson-DeWitt and Teresa G. The Gale Encyclopedia of Medicine. Vol. 2. 3rd ed. Detroit: Gale, 2006.
- Cozad J (March 1996). "Infectious mononucleosis". The Nurse Practitioner 21 (3): 14–6, 23, 27–8. doi:10.1097/00006205-199603000-00002. PMID 8710247.
- "How Long Is Mono Contagious?". Kidshealth.org. Retrieved 2009-11-27.
- ped/705 at eMedicine
- "The Lymphatic System". Lymphangiomatosis & Gorham's disease Alliance. Retrieved 2010-02-08.
- Ghosh, Amit K.; Habermann, Thomas (2007). Mayo Clinic Internal Medicine Concise Textbook. Informa Healthcare. ISBN 1-4200-6749-4.
- Rosenfield RE; Schmidt PJ; Calvo RC; McGinniss MH (1965). "Anti-i, a frequent cold agglutinin in infectious mononucleosis". Vox Sanguinis 10 (5): 631–634. doi:10.1111/j.1423-0410.1965.tb01418.x. PMID 5864820.
- Longmore, Murray; Ian Wilkinson; Tom Turmezei; Chee Kay Cheung (2007). Oxford Handbook of Clinical Medicine, 7th edition. Oxford University Press. p. 389. ISBN 0-19-856837-1.
- Hoagland RJ (June 1975). "Infectious mononucleosis". Primary care 2 (2): 295–307. PMID 1046252.
- Bravender, T (August 2010). "Epstein-Barr virus, cytomegalovirus, and infectious mononucleosis". Adolescent medicine: state of the art reviews 21 (2): 251–64, ix. PMID 21047028.
- Mark H. Beers ... (2006). Beers MH, Porter RS, Jones TV, Kaplan JL, Berkwits M, editors., eds. The Merck manual of diagnosis and therapy (18th ed.). Whitehouse Station (NJ): Merck Research Laboratories. ISBN 0-911910-18-2.
- Putukian, M; O'Connor, FG; Stricker, P; McGrew, C; Hosey, RG; Gordon, SM; Kinderknecht, J; Kriss, V; Landry, G (July 2008). "Mononucleosis and athletic participation: an evidence-based subject review" (PDF). Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine 18 (4): 309–15. doi:10.1097/JSM.0b013e31817e34f8. PMID 18614881. Retrieved 18 June 2013.
- National Center for Emergency Medicine Informatics - Mononucleosis http://www.ncemi.org/cse/cse0314.htm
- Candy B, Hotopf M; Hotopf (2006). Candy, Bridget, ed. "Steroids for symptom control in infectious mononucleosis". Cochrane Database Syst Rev 3 (3): CD004402. doi:10.1002/14651858.CD004402.pub2. PMID 16856045.
- Candy B, Hotopf M.; Hotopf (2006). Candy, Bridget, ed. "Steroids for symptom control in infectious mononucleosis". Cochrane Database of Systematic Reviews 3 (4): CD004402. doi:10.1002/14651858.CD004402.pub2. PMID 16856045.
- "Infectious Mononucleosis". WebMD. January 24, 2006. Retrieved 2006-07-10.
- Antibiotic Expert Group. Therapeutic guidelines: Antibiotic. 13th ed. North Melbourne: Therapeutic Guidelines; 2006.
- Torre D, Tambini R; Tambini (1999). "Acyclovir for treatment of infectious mononucleosis: a meta-analysis". Scand. J. Infect. Dis. 31 (6): 543–7. doi:10.1080/00365549950164409. PMID 10680982.
- Balfour HH, Hokanson KM, Schacherer RM; Hokanson; Schacherer; Fietzer; Schmeling; Holman; Vezina; Brundage (2007). "A virologic pilot study of valacyclovir in infectious mononucleosis". J. Clin. Virol. 39 (1): 16–21. doi:10.1016/j.jcv.2007.02.002. PMID 17369082.
- Simon (March 2003). "The Effect of Valacyclovir and Prednisolone in Reducing Symptoms of EBV Illness In Children: A Double-Blind, Placebo-Controlled Study". International Pediatrics 18 (3): 164–169.
- Rafailidis PI, Mavros MN, Kapaskelis A, Falagas, ME; Mavros; Kapaskelis; Falagas (2010). "Antiviral treatment for severe EBV infections in apparently immunocompetent patients". J. Clin. Virol. 49 (3): 151–7. doi:10.1016/j.jcv.2010.07.008. PMID 20739216.
- "Glandular fever - NHS". National Health Service (NHS). 2010-09-09. Retrieved 2010-09-09.
- American Medical Society for Sports Medicine (24 April 2014), "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation (American Medical Society for Sports Medicine), retrieved 29 July 2014, which cites
- Putukian, M; O'Connor, FG; Stricker, P; McGrew, C; Hosey, RG; Gordon, SM; Kinderknecht, J; Kriss, V; Landry, G (Jul 2008). "Mononucleosis and athletic participation: an evidence-based subject review". Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine 18 (4): 309–15. doi:10.1097/JSM.0b013e31817e34f8. PMID 18614881.
- Spielmann, AL; DeLong, DM; Kliewer, MA (Jan 2005). "Sonographic evaluation of spleen size in tall healthy athletes.". AJR. American journal of roentgenology 184 (1): 45–9. doi:10.2214/ajr.184.1.01840045. PMID 15615949.
- Jensen, Hal B (June 2000). "Acute complications of Epstein-Barr virus infectious mononucleosis". Current Opinion in Pediatrics (Lippincott Williams & Wilkins, Inc.) 12 (3): 263–268. doi:10.1097/00008480-200006000-00016. ISSN 1040-8703. PMID 10836164.
- Aghenta A; Osowo, A; Thomas, J (May 2008). "Symptomatic atrial fibrillation with infectious mononucleosis". Canadian Family Physician (College of Family Physicians of Canada) 54 (5): 695–696. PMC 2377232. PMID 18474702.
- Ascherio A, Munger KL; Munger (2007). "Environmental risk factors for multiple sclerosis. Part I: the role of infection". Ann. Neurol. 61 (4): 288–99. doi:10.1002/ana.21117. PMID 17444504.
- Pattle, SB; Farrell, PJ (November 2006). "The role of Epstein-Barr virus in cancer.". Expert Opinion on Biological Therapy (Informa) 6 (11): 1193–205. doi:10.1517/147125220.127.116.113. PMID 17049016. Retrieved June 23, 2014.
- Sitki-Green D, Covington M, Raab-Traub N; Covington; Raab-Traub (February 2003). "Compartmentalization and Transmission of Multiple Epstein-Barr Virus Strains in Asymptomatic Carriers". Journal of Virology 77 (3): 1840–1847. doi:10.1128/JVI.77.3.1840-1847.2003. PMC 140987. PMID 12525618.
- Hadinoto V, Shapiro M, Greenough TC, Sullivan JL, Luzuriaga K, Thorley-Lawson DA; Shapiro; Greenough; Sullivan; Luzuriaga; Thorley-Lawson (February 1, 2008). "On the dynamics of acute EBV infection and the pathogenesis of infectious mononucleosis". Blood 111 (3): 1420–1427. doi:10.1182/blood-2007-06-093278. PMC 2214734. PMID 17991806.
- Altschuler, EL (1 September 1999). "Antiquity of Epstein-Barr virus, Sjögren's syndrome, and Hodgkin's disease--historical concordance and discordance". Journal of the National Cancer Institute 91 (17): 1512–3. doi:10.1093/jnci/91.17.1512A. PMID 10469761. Retrieved 17 June 2013.
- Evans, AS (March 1974). "The history of infectious mononucleosis". The American journal of the medical sciences 267 (3): 189–95. doi:10.1097/00000441-197403000-00006. PMID 4363554. Retrieved 17 June 2013.
- Н. Филатов: Лекции об острых инфекционных болезнях у детей [N. Filatov: Lektsii ob ostrikh infeksionnîkh boleznyakh u dietei]. 2 volumes. Moscow, A. Lang, 1887.
- E. Pfeiffer: Drüsenfieber. Jahrbuch für Kinderheilkunde und physische Erziehung, Wien, 1889, 29: 257–264.
- Elsevier, Dorland's Illustrated Medical Dictionary, Elsevier. Headword "mononucleosis".
- Sprunt TPV, Evans FA. Mononuclear leukocytosis in reaction to acute infection (infectious mononucleosis). Bulletin of the Johns Hopkins Hospital. Baltimore, 1920;31:410-417.
- Miller, George (December 21, 2006). "Book Review: Epstein–Barr Virus". New England Journal of Medicine 355 (25): 2708–2709. doi:10.1056/NEJMbkrev39523. Retrieved 17 June 2013.
- Henle, G; Henle, W; Diehl, V (January 1968). "Relation of Burkitt's tumor-associated herpes-type virus to infectious mononucleosis" (PDF). Proceedings of the National Academy of Sciences of the United States of America 59 (1): 94–101. doi:10.1073/pnas.59.1.94. PMC 286007. PMID 5242134. Retrieved 18 June 2013.
|Wikimedia Commons has media related to Infectious mononucleosis.|